Assessment the equivalence of the bioanalogue insulin lizpro biphasic 25 (Geropharm-bio, Russia) and Humalog® Mix 25 (Lilly France, France) using the euglycemic hyperinsulinum clamp method on healthy volonters

Background: Modern medicine requires use of effective antidiabetic drugs that can imitate the natural profile of insulin in the body of patients with diabetes mellitus. Examples of such preparations include biphasic insulin lispro, which is a mixture of insulin lispro ultra-short action and insulin lispro protamine suspension with prolonged effect. The clinical trials (CT) program for biosimilar insulins contains pharmacology studies: pharmacokinetics (PK), pharmacodynamics (PD) and clinical safety studies.

Aims: To demonstrate Biphasic Insulin Lispro 25, suspension for subcutaneous administration, 100 U/ml (GEROPHARM-Bio, Russia) and Humalog® Mix 25, suspension for subcutaneous administration, 100 U/ml (Lilly France, France) have comparable pharmacokinetic profiles under conditions of hyperinsulinemic euglycemic clamp (HEC) in healthy volunteers.

Materials and methods: The study was conducted on 48 healthy men aged between 18 to 50 years. This was a double-blind, randomized, crossover study of comparative pharmacokinetics of drugs. The investigational products (IP) were administered before the clamp in a single dose of 0.4 U/kg subcutaneously in the abdominal wall. Regular blood sampling was performed during the study. The insulin concentrations in the samples were determined using an ELISA method. The results of the determination were used to calculate the PK parameters and construct the concentration-time curves. Adjust glucose infusion rates were based on blood glucose measurements. These data were used to calculate the PD parameters.

Results: Our results demonstrated that Biphasic Insulin Lispro 25 and Humalog® Mix 25 have comparable PK and PD profiles under conditions of HEC in healthy volunteers. The confidence intervals for the ratio of the geometric mean for Cins.max and AUCins.0–12 were 87.75–99.90% and 83.76–96.98% respectively, which were well within 80–125% limits for establishing comparability.

Conclusions: Biphasic Insulin Lispro 25 and Humalog® Mix 25 are equivalent based on this CT applying the HEC technique in healthy volunteers.

Insulin lispro, biosimilar, clinical trials, pharmacokinetics, pharmacodynamics, comparability, hyperinsulinemic euglycemic clamp

1. Дедов И.И., Мельниченко Г.А. Эндокринология. Национальное руководство. Краткое издание. – М.: ГЭОТАР-Медиа; 2015. [Dedov II, Melnichenko GA. Endokrinologiya. National guidelines. Short edition. Moscow: GEOTAR-Media; 2015. (In Russ.)]

2. Zhang P, Zhang X, Brown J, et al. Erratum to “Global healthcare expenditure on diabetes for 2010 and 2030” Diabetes Res Clin Pract. 2011;92(2):301. doi: 10.1016/j.diabres.2010.12.025

3. Dunn CJ, Plosker GL. Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus. Pharmacoeconomics. 2002;20(14):989-1025. doi: 10.2165/00019053-200220140-00004

4. Roach P, Woodworth JR. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet. 2002;41(13):1043-1057. doi: 10.2165/00003088-200241130-00003

5. White JR, Jr., Campbell RK, Hirsch I. Insulin analogues: new agents for improving glycemic control. Postgrad Med. 1997;101(2):58-60, 63-55, 70. doi: 10.3810/pgm.1997.02.157

6. Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab. 2007;9(5):630-639. doi: 10.1111/j.1463-1326.2006.00654.x

7. Федеральный закон Российской Федерации № 61 от 12 апреля 2010 «Об обращении лекарственных средств». [Federal Law of the Russian Federation № 61 of 12 Apr 2010 " Ob obrashchenii lekarstvennykh sredstv". (In Russ.)]

8. Davies M, Dahl D, Heise T, et al. Introduction of biosimilar insulins in Europe. Diabet Med. 2017;34(10):1340-1353. doi: 10.1111/dme.13400

9. European Medicines Agency. Abasaglar Insulin Glargine. EPAR Summary for the Public. 2015.

10. European Medicines Agency. Lusduna Insulin Glargine. EPAR Summary for the Public. 2017.

11. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. 2015.

12. European Medicines Agency. Guideline on similar biological medicinal products. 2005.

13. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2015.

14. European Medicines Agency. Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins. 2007.

15. European Medicines Agency. Guideline on the investigation of bioequivalence. 2010.

16. European Medicines Agency. Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins. 2007.

17. Правила проведения исследований биологических лекарственных средств Евразийского экономического союза, глава 15.7 «Доклиническая и клиническая разработка биоаналогичных (биоподобных) лекарственных препаратов, содержащих рекомбинантный инсулин и аналоги инсулина». [Rules for the Study of Biological Medicines of the Eurasian Economic Union ", chapter 15.7 “Doklinicheskaya i klinicheskaya razrabotka bioanalogichnykh (biopodobnykh) lekarstvennykh preparatov, soderzhashchikh rekombinantnyy insulin i analogi insulina”. (In Russ.)]

18. Разработка биоаналогичных (биоподобных) лекарственных препаратов, содержащих в качестве фармацевтической субстванции генно-инженерный инсулин человека или аналоги инсулина человека. В кн.: Руководство по экспертизе лекарственных средств. Том IV. – М.: Полиграф-плюс; 2014. [Razrabotka bioanalogichnykh (biopodobnykh) lekarstvennykh preparatov, soderzhashchikh v kachestve farmatsevticheskoy substvantsii genno-inzhenernyy insulin cheloveka ili analogi insulina cheloveka. In: Rukovodstvo po ekspertize lekarstvennykh sredstv.Vol. IV. Moscow: Poligraf-plyus; 2014. (In Russ.)]

19. Решение № 89 от 3 ноября 2016 года «Об утверждении правил проведения исследований биологических лекарственных средств Евразийского экономического союза». [Decision № 89 of Nov 3 2016 " Ob utverzhdenii pravil provedeniya issledovaniy biologicheskikhlekarstvennykh sredstv Evraziyskogo ekonomicheskogo soyuza". (In Russ.)]

20. Heinemann L, Anderson JH, Jr. Measurement of insulin absorption and insulin action. Diabetes Technol Ther. 2004;6(5):698-718. doi: 10.1089/dia.2004.6.698

21. Heise T, Zijlstra E, Nosek L, et al. Euglycaemic glucose clamp: what it can and cannot do, and how to do it. Diabetes Obes Metab. 2016;18(10):962-972. doi: 10.1111/dom.12703

22. Hompesch M, Rave K. An analysis of how to measure glucose during glucose clamps: are glucose meters ready for research? J Diabetes Sci Technol. 2008;2(5):896-898. doi: 10.1177/193229680800200522

23. Rabiee A, Magruder JT, Grant C, et al. Accuracy and reliability of the Nova StatStrip(R) glucose meter for real-time blood glucose determinations during glucose clamp studies. J Diabetes Sci Technol. 2010;4(5):1195-1201. doi: 10.1177/193229681000400519

24. Lindquist KA, Chow K, West A, et al. The StatStrip glucose monitor is suitable for use during hyperinsulinemic euglycemic clamps in a pediatric population. Diabetes Technol Ther. 2014;16(5):298-302. doi: 10.1089/dia.2013.0288

25. Heise T, Weyer C, Serwas A, et al. Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin. Diabetes Care. 1998;21(5):800-803. doi: 10.2337/diacare.21.5.800

26. Решение № 85 от 3 ноября 2016 года «Правила проведения исследований биоэквивалентности лекарственных препаратов в рамках Евразийского Экономического Союза». [Decision № 85 of 3 Nov 2016 “Pravila provedeniya issledovaniy bioekvivalentnosti lekarstvennykh preparatov v ramkakh Evraziyskogo Ekonomicheskogo Soyuza”. (In Russ.)]

27. Filipe A, Pedroso P, Almeida S, et al. Bioequivalence study of two formulations of ibandronic acid 150-mg film-coated tablets in healthy volunteers under fasting conditions: a randomized, open-label, three-way, reference-replicated crossover study. Drugs R D. 2014;14(2):105-112. doi: 10.1007/s40268-014-0044-x

28. du Prel JB, Hommel G, Rohrig B, Blettner M. Confidence interval or p-value?: part 4 of a series on evaluation of scientific publications. Dtsch Arztebl Int. 2009;106(19):335-339. doi: 10.3238/arztebl.2009.0335